AI-powered evaluation using the Model Context Optimization BS Detection Framework, based solely on publicly available website content.
Based on 587 businesses audited.
Medical Devices, Pharma & Biotech BS: Puma Biotechnology (NERLYNX) (nerlynx.com)
This is a high-substance, low-bullshit site that prioritizes clinical evidence and patient safety over marketing fluff. It is a benchmark for pharmaceutical transparency, where the ‘Signal’ is entirely comprised of ‘Substance.’
Implement JSON-LD Drug and Organization schema to resolve the technical authority gap. Consolidate the multiple ‘You are leaving this website’ H2 tags that clutter the heading hierarchy. Add direct outbound links to ClinicalTrials.gov or PubMed for the cited studies to provide a complete external proof path. Ensure the mentor program’s ‘compensated’ disclaimer is more visually distinct to maintain current high levels of trust.
Information density is exceptionally high. Instead of power words, the site uses specific nouns and technical protocols such as ‘extended adjuvant therapy,’ ‘trastuzumab-based treatment,’ and ‘small molecule targeted therapy.’ Specific metrics are abundant, such as the ‘34% lower risk of recurrence’ in the ExteNET trial and the exact population count of ‘2,840 women.’ The only penalty comes from the necessary but high repetition of diarrhea management instructions across all four pages.
If your content is buried under div based wrappers, AI will treat it as noise instead of meaning. Check your Machine Readability Index with a free one page structural interpretation.
There is no detectable semantic drift. The homepage H1 (Reducing Recurrence) is immediately and consistently supported by the sub-pages which detail exactly how the drug reduces recurrence for both early-stage and metastatic patients. The messaging remains clinically focused without shifting into generic ‘wellness’ or ‘lifestyle’ promises that often plague pharmaceutical marketing.
Transition from a collection of strings to a machine verifiable identity. Generate your Clinical SEO Strategy to establish a robust Knowledge Graph Topology and eliminate semantic black holes.
The site avoids common trust theatre traps like unverified star ratings or fake badges. While it uses patient testimonials (Sherry H, Edwina L), they are strictly regulated with legal disclaimers noting compensation and that experiences vary. The proof_links_count of 3 reflects clinical evidence and patient information links rather than social media fluff.
Proof density is significantly higher than the industry average. Every major efficacy claim is tied to a specific clinical trial (ExteNET or the metastatic phase 3 trial), and the site provides both relative risk reductions (34%) and absolute numbers (94.2% vs 91.9%) to ensure full transparency. There are 10+ instances of specific, verifiable evidence across the analyzed pages.
To see how the methodology translates into real diagnostic output, review a full executive level analysis applied to a global fashion retailer. View the Mango Executive SEO Strategy for a concrete example of how structural gaps, semantic weaknesses, and conversion friction are surfaced in practice.
The value proposition is drug-specific and cannot be copy-pasted onto a competitor. While it uses industry jargon like ‘clinical trial data’ and ‘mechanism of action,’ these are presented as verifiable technical deliverables. Boilerplate sections are minimal, though the ‘Support for you and your family’ section uses standard industry templates for patient assistance programs.
The primary authority gap is technical; the crawl shows null for schema_json, indicating a lack of structured data to identify the organization or the drug via Schema.org/Drug properties. While the brand authority is clear through its clinical data, the digital footprint lacks the structured verification (sameAs links to regulatory filings) expected of a technical leader.
There is no disconnect between claims and evidence. Performance claims like ‘59% reduction in the risk of central nervous system (CNS) metastases’ are cited as part of a 5-year special analysis of the ExteNET study. The site transparently admits when conclusions cannot be drawn from specific sub-analyses, which is the opposite of bullshit.
Medical Devices, Pharma & Biotech BS: Puma Biotechnology (NERLYNX) (nerlynx.com)
The content perfectly matches the Pharma & Biotech industry category. It focuses exclusively on the therapeutic area of HER2+ breast cancer and provides granular clinical trial data for the drug neratinib.
Every retrieval error rooted in "wrong page surfaced" begins with one failure: unstable URL identity. Read the URL & Canonical Technical Guide to learn how consistent paths and canonical alignment preserve semantic cohesion.
“The score of 14 is driven primarily by technical gaps (missing schema) and necessary concept repetition. In all other pillars, the site scores near-zero for BS because it replaces generic marketing claims with forensic clinical data and specific regulatory-approved safety protocols.”